CEFPROZIL TABLETS
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
09-10-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CEFPROZIL (CEFPROZIL MONOHYDRATE)
Fáanlegur frá:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC númer:
J01DC10
INN (Alþjóðlegt nafn):
CEFPROZIL
Skammtar:
250MG
Lyfjaform:
TABLET
Samsetning:
CEFPROZIL (CEFPROZIL MONOHYDRATE) 250MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
SECOND GENERATION CEPHALOSPORINS
Vörulýsing:
Active ingredient group (AIG) number: 0127613003; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2009-08-20
Vara einkenni
_ _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
CEFPROZIL TABLETS
CEFPROZIL TABLETS
(250 MG AND 500 MG OF CEFPROZIL AS CEFPROZIL MONOHYDRATE)
USP
ANTIBIOTIC
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
DATE OF REVISION:
October 9, 2019
CONTROL NO: 231653
_ _
_ _
_Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND ADMINISTRATION
.............................................................................
10
OVERDOSAGE
...............................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 12
PART II: SCIENTIFIC INFORMATION
..............................................................................
13
PHARMACEUTICAL INFORMATION
.........................................................................
13
TOXICOLOGY
................................................................................................................
18
REFERENCES
.................................................................................................................
25
PART III: CONSUMER INFORMATION
.............................
Lestu allt skjalið
